Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094973 | 1.00 | GPR119 (0.41) | GPR119MMP13KDM4EMAPTTHRB | |
| SCHEMBL4096502 | 0.84 | GPR119 (0.49) | GPR119MMP13KDM4EMAPTTHRB | |
| SCHEMBL4096500 | 0.84 | GPR119 (0.49) | GPR119MMP13KDM4EMAPTTHRB | |
| SCHEMBL4168857 | 0.80 | GPR119 (0.49) | GPR119 | |
| SCHEMBL4168862 | 0.80 | GPR119 (0.49) | GPR119 | |
| SCHEMBL4104864 | 0.79 | GPR119 (0.44) | GPR119KDM4E | |
| SCHEMBL4166576 | 0.78 | GPR119 (0.52) | GPR119 | |
| SCHEMBL4166579 | 0.78 | GPR119 (0.52) | GPR119 | |
| SCHEMBL4094850 | 0.78 | GPR119 (0.46) | GPR119MMP13KDM4E | |
| SCHEMBL4094884 | 0.76 | GPR119 (0.42) | GPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221644-A1 | Gpcr Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221644-A1 | Gpcr Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221644-A1 | Gpcr Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| WO-2007003961-A2 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221644-A1 | Gpcr Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885MMP13 4024/4885KDM4E 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.